Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COX-2: separating myth from reality.

F McKenna1

  • 1Trafford General Hospital, Davyhulme, Manchester, UK.

Scandinavian Journal of Rheumatology. Supplement
|July 28, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anxiety in a Specialist Perinatal Mental Health Service: patient characteristics, management, and outcomes.

Irish journal of psychological medicine·2023
Same author

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.

Rheumatology (Oxford, England)·2007
Same author

COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2006
Same author

Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study.

Journal of neuroimmunology·2002
Same author

Application of actinomycetes to soil to ameliorate water repellency.

Letters in applied microbiology·2002
Same author

Wegener's granulomatosis and rheumatoid arthritis overlap.

Rheumatology (Oxford, England)·2002
Same journal

Abstract of the 35th Scandinavian Congress of Rheumatology, September 20-23, 2014, Stockholm, Sweden.

Scandinavian journal of rheumatology. Supplement·2014
Same journal

Abstracts of the 34th Scandinavian Congress of Rheumatology. Copenhagen, Denmark. September 2-5, 2012.

Scandinavian journal of rheumatology. Supplement·2012
Same journal

How should impaired morning function in rheumatoid arthritis be treated?

Scandinavian journal of rheumatology. Supplement·2011
Same journal

Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice.

Scandinavian journal of rheumatology. Supplement·2011
Same journal

How should morning function in rheumatoid arthritis be assessed? Bibliographic study of current assessment.

Scandinavian journal of rheumatology. Supplement·2011
Same journal

How much is a reduction in morning stiffness worth to patients with rheumatoid arthritis?

Scandinavian journal of rheumatology. Supplement·2011
See all related articles

Nonsteroidal anti-inflammatory drugs (NSAIDs) targeting COX-2 selectively may offer improved gastrointestinal safety. However, current NSAIDs inhibit COX-1, causing upper GI damage, necessitating development of specific COX-2 inhibitors.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Rheumatology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) enzymes, with varying selectivity for COX-1 and COX-2.
  • Concerns exist regarding the upper gastrointestinal (GI) toxicity associated with NSAID use.
  • The hypothesis that selective COX-2 inhibition improves GI safety is debated.

Purpose of the Study:

  • To evaluate the relationship between NSAID selectivity for COX-2 over COX-1 and upper GI safety.
  • To assess the evidence supporting the use of COX-2 selective inhibitors for improved GI outcomes.
  • To highlight the need for specific COX-2 inhibitors without COX-1 activity.

Main Methods:

  • Review of existing literature on NSAID selectivity and toxicity.

Related Experiment Videos

  • Analysis of arguments linking COX-2/COX-1 inhibition ratios to upper GI safety.
  • Discussion of the limitations of current NSAID evaluations in the absence of endoscopic data.

    • Main Results:

    • Current NSAIDs inhibit COX-1, leading to upper GI mucosal damage.
    • Claims of improved safety with COX-2 selective NSAIDs lack direct endoscopic evidence in patients.
    • No currently available NSAID is a specific COX-2 inhibitor without COX-1 activity.

    Conclusions:

    • Specific COX-2 inhibitors that do not inhibit COX-1 are needed.
    • Development of such agents is ongoing, with clinical trials underway.
    • The advent of safe and effective specific COX-2 inhibitors could revolutionize rheumatic disease treatment.